Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Integromics Collaborates With TATAA Biocenters

By Drug Discovery Trends Editor | March 8, 2010

Integromics S.L., the leading provider of bioinformatics solutions to gene expression researchers, has announced an exciting collaboration with the TATAA Biocenters in Sweden and the Czech Republic, to provide expert training in qPCR data analysis using RealTime StatMiner. Professor Mikael Kubista, Chairman of TATAA Biocenter, explained: “We have been teaching courses in real-time qPCR since 2001, and continually update our course programs to reflect the latest technological advances. Our data analysis courses are designed for researchers, technicians and post-graduate students without specialist bioinformatics training, and RealTime StatMiner provides these users with an array of powerful, easy-to-use data analysis tools.”

Imad Yassin, Commercial Director at Integromics, added: “Our sophisticated and powerful software packages are designed to provide customers with all the features they need, in a user-friendly format. The intuitive interface and unique ‘guided workflow’ approach of RealTime StatMiner provide an unparalleled solution for in-house analysis of qPCR and microarray data, offering step-by-step guidance for straightforward analysis and interpretation. We are excited that the TATAA Biocenter – a respected leader in PCR services and training – has recognized the value of RealTime StatMiner, and wishes to share the benefits of this comprehensive package with its customers.”

Date: March 4, 2010
Source: Integromics S.L.


Filed Under: Drug Discovery

 

Related Articles Read More >

EVEREST lead investigator on why Dupixent sets a new bar for treating coexisting CRSwNP and asthma
Sanders, King target DTC pharma ads but the industry worries more about threats to its $2B R&D model
Zoliflodacin wins FDA nod for treatment of gonorrhea
FDA approved ENFLONSIA for the prevention of RSV in Infants
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE